These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
389 related items for PubMed ID: 15389804
1. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Wikström P, Lindahl C, Bergh A. Prostate; 2005 Feb 01; 62(2):148-64. PubMed ID: 15389804 [Abstract] [Full Text] [Related]
2. Androgen-independent prostate cancer progression in the TRAMP model. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Cancer Res; 1997 Nov 01; 57(21):4687-91. PubMed ID: 9354422 [Abstract] [Full Text] [Related]
3. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Tang Y, Wang L, Goloubeva O, Khan MA, Zhang B, Hussain A. Clin Cancer Res; 2008 May 15; 14(10):2936-43. PubMed ID: 18483360 [Abstract] [Full Text] [Related]
4. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW. Prostate; 2007 May 15; 67(7):685-91. PubMed ID: 17342752 [Abstract] [Full Text] [Related]
5. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. Cancer Res; 1999 May 01; 59(9):2203-9. PubMed ID: 10232609 [Abstract] [Full Text] [Related]
6. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Yeh IT, Reddick RL, Kumar AP. Prostate; 2009 May 15; 69(7):755-60. PubMed ID: 19170049 [Abstract] [Full Text] [Related]
7. Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Johnson MA, Iversen P, Schwier P, Corn AL, Sandusky G, Graff J, Neubauer BL. Prostate; 2005 Mar 01; 62(4):322-38. PubMed ID: 15389779 [Abstract] [Full Text] [Related]
8. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Martiniello-Wilks R, Dane A, Mortensen E, Jeyakumar G, Wang XY, Russell PJ. Anticancer Res; 2003 Mar 01; 23(3B):2633-42. PubMed ID: 12894551 [Abstract] [Full Text] [Related]
9. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Cancer Res; 1997 Aug 15; 57(16):3325-30. PubMed ID: 9269988 [Abstract] [Full Text] [Related]
10. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. Jeet V, Ow K, Doherty E, Curley B, Russell PJ, Khatri A. Prostate; 2008 Apr 01; 68(5):548-62. PubMed ID: 18247402 [Abstract] [Full Text] [Related]
11. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Bruckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. Oncogene; 2000 Nov 02; 19(46):5251-8. PubMed ID: 11077442 [Abstract] [Full Text] [Related]
12. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice. Bono AV, Montironi R, Pannellini T, Sasso F, Mirone V, Musiani P, Iezzi M. Prostate Cancer Prostatic Dis; 2008 Nov 02; 11(4):377-83. PubMed ID: 18379588 [Abstract] [Full Text] [Related]
13. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW. J Urol; 2005 May 02; 173(5):1778-83. PubMed ID: 15821586 [Abstract] [Full Text] [Related]
14. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, Fong G, Xuan JW. Oncogene; 2005 Feb 24; 24(9):1510-24. PubMed ID: 15674347 [Abstract] [Full Text] [Related]
15. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Cancer Res; 2002 Mar 01; 62(5):1370-6. PubMed ID: 11888907 [Abstract] [Full Text] [Related]
16. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Johansson A, Jones J, Pietras K, Kilter S, Skytt A, Rudolfsson SH, Bergh A. Prostate; 2007 Nov 01; 67(15):1664-76. PubMed ID: 17854058 [Abstract] [Full Text] [Related]
17. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model. Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW. Prostate; 2003 Jun 01; 55(4):308-16. PubMed ID: 12712410 [Abstract] [Full Text] [Related]
18. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Frost GI, Lustgarten J, Dudouet B, Nyberg L, Hartley-Asp B, Borgström P. Microvasc Res; 2005 Jan 01; 69(1-2):1-9. PubMed ID: 15797254 [Abstract] [Full Text] [Related]
19. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA. Cancer Res; 1997 Mar 01; 57(5):900-6. PubMed ID: 9041192 [Abstract] [Full Text] [Related]
20. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Cancer Res; 2007 Jun 15; 67(12):5789-97. PubMed ID: 17575146 [Abstract] [Full Text] [Related] Page: [Next] [New Search]